At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
TAS-205 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase IIa Study of TAS-205 in Patients With Duchenne Muscular Dystrophy
In Brief
A Phase 2 clinical trial evaluating TAS-205 and Placebo for Duchenne Muscular Dystrophy. Completed, enrolled 36 participants across 11 sites.
Detailed Summary
The objective of this study is to evaluate the efficacy after 24-week repeated oral doses of TAS-205 in patients with Duchenne Muscular Dystrophy (DMD) in an exploratory manner.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDuchenne Muscular Dystrophy
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartMay 2016
Primary CompletionMay 2017
Study CompletionOct 2017
TodayJul 2026
First PostedApr 26, 2016
Enrollment StartMay 1, 2016
Primary CompletionMay 15, 2017
Study CompletionOct 17, 2017
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 10.2 years ago
Interventions
TAS-205drug
2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
Placebodrug
1 group: Placebo group. Oral administration for 24 weeks, BID after meal